This hypothesis is supported by preclinical studies of incretin mimetics across cellular and animal models of dopaminergic cell loss and PD [35, 61, 62] and, additionally, by the successful efficacy of the GLP-1 receptor agonist Exenatide in patients with moderate PD [26–30]. Here, GLP1R is linked to Parkinson disease.